

Ganirelix Formulation

| Vers 5.3 | sion | Revision Date: 16.10.2020 | SDS Number: 22210-00016 | | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 | | |
|-------------------------------------------------------------------|---------------------------------------|------------------------------------|----------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------|--|--|
| 1. P | 1. PRODUCT AND COMPANY IDENTIFICATION | | | | | | |
| | Product name | | : | Ganirelix Formula | ation | | |
| | Manufa | acturer or supplier's c | detai | ils | | | |
| | Compa | | : | Organon & Co. | | | |
| | Address | | : | 30 Hudson Street, 33nd floor Jersey City, New Jersey, U.S.A 07302 | | | |
| | Telephone | | : | : 551-430-6000 | | | |
| | Emergency telephone number | | r : | : 215-631-6999 | | | |
| | E-mail address | | : | EHSSTEWARD@organon.com | | | |
| | | mended use of the cl mended use | hem : | ical and restriction Pharmaceutical | ons on use | | |
| 2. H | 2. HAZARDS IDENTIFICATION | | | | | | |
| Manufacture, Storage and Import of Hazardous Chemicals Rules 1989 | | | | | | | |
| | Classification | | | | | | |
| | Not cla | ssified as hazardous a | ccor | ding to criteria laid | down in Part I of Schedule-1. | | |
| | GHS C | lassification | | | | | |

| GHS Classification | | |
|----------------------------------------------------|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Reproductive toxicity | : | Category 1B |
| Specific target organ toxicity - repeated exposure | : | Category 1 (Bone marrow, Liver, Adrenal gland, spleen, Ovary) |
| GHS label elements | | |
| Hazard pictograms | : | |
| Signal word | : | Danger |
| Hazard statements | : | H360Fd May damage fertility. Suspected of damaging the un- born child. |
| | | H372 Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure. |
| Precautionary statements | : | Prevention: |
| | | P203 Obtain, read and follow all safety instructions before use.P260 Do not breathe mist or vapours.P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product. |
| | | |



Ganirelix Formulation

| /ersion 5.3 | Revision Date: 16.10.2020 | - | S Number: 210-00016 | Date of last issue: 13. Date of first issue: 15. | | | |
|----------------|------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|--------------------------|--|--|
| | | P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. | | | | | |
| | | | Response: P318 IF expos | ed or concerned, get med | lical advice. | | |
| | | | Storage: P405 Store loc | ked up. | | | |
| | | | Disposal: P501 Dispose of contents/ container to an approved wasted disposal plant. | | | | |
| | hazards which do no known. | ot res | ult in classifica | tion | | | |
| B. COMPO | SITION/INFORMATIC | ON ON | I INGREDIENTS | 5 | | | |
| Subst | ance / Mixture | : | Mixture | | | | |
| Comp | oonents | | | | | | |
| Chem | ical name | | | CAS-No. | Concentration (% w/w) | | |
| Ganire | elix | | | 124904-93-4 | >= 0.01 - < 0.1 | | |
| . FIRST A | | | | | | | |
| Gener | ral advice | : | In the case of accident or if you feel unwell, seek medical a vice immediately. When symptoms persist or in all cases of doubt seek medic advice. | | | | |
| lf inha | lled | : | If inhaled, remo Get medical atte | | | | |
| In cas | e of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. | | | | |
| In cas | e of eye contact | : | Flush eyes with | water as a precaution. | s and persists. | | |
| lf swa | llowed | : | Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. | | | | |

May damage fertility. Suspected of damaging the unborn Most important symptoms : and effects, both acute and child. Causes damage to organs through prolonged or repeated exposure

| ection, |
|---------|
| ment |
|). |
| |
| |

5. FIREFIGHTING MEASURES

delayed



Ganirelix Formulation

| Version 5.3 | Revision Date: 16.10.2020 | - | 0S Number: 210-00016 | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 | | | |
|------------------------------|----------------------------------------------------------------------------------------------------------------------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| Suitable extinguishing media | | : | Water spray Alcohol-resistant f Carbon dioxide (C Dry chemical | | | | |
| | Unsuitable extinguishing media Specific hazards during fire- fighting Hazardous combustion prod- ucts | | None known. | | | | |
| Speci | | | Exposure to combustion products may be a hazard to health. | | | | |
| Hazar | | | No hazardous cor | nbustion products are known | | | |
| Speci ods | fic extinguishing meth- | : | Use extinguishing measures that are appropriate to lo cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is s so. Evacuate area. | | | | |
| | Special protective equipment for firefighters | | In the event of fire, wear self-contained breathing apparatu Use personal protective equipment. | | | | |
| 6. ACCIDENTAL RELEASE MEA | | | RES | | | | |
| tive e | Personal precautions, protec- tive equipment and emer- gency procedures | | Follow safe handl | ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8). | | | |
| Enviro | onmental precautions | : | Prevent spreading barriers). Retain and dispos | akage or spillage if safe to do so. g over a wide area (e.g. by containment or oil se of contaminated wash water. should be advised if significant spillages | | | |
| | ods and materials for nment and cleaning up | : | For large spills, pr ment to keep mat be pumped, store Clean up remainin bent. Local or national n posal of this mate employed in the c mine which regula Sections 13 and 1 | absorbent material. Tovide dyking or other appropriate contain- erial from spreading. If dyked material can recovered material in appropriate container. Ing materials from spill with suitable absor- regulations may apply to releases and dis- rial, as well as those materials and items leanup of releases. You will need to deter- ations are applicable. 5 of this SDS provide information regarding tional requirements. | | | |

7. HANDLING AND STORAGE

| Technical measures | : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
|-------------------------|------------------------------------------------------------------------------------|
| Local/Total ventilation | : If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : Do not get on skin or clothing. |



Basis

Ganirelix Formulation

| Versior 5.3 | Revision Date: 16.10.2020 | SDS Number: 22210-00016 | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 |
|-----------------------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| | | Do not swallow Avoid contact Wash skin tho Handle in acco practice, base sessment Keep containe Do not eat, dri | |
| Conditions for safe storage | | Store locked u Keep tightly cl | osed. |
| Ma | aterials to avoid | | dance with the particular national regulations. vith the following product types: ng agents |

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters Components CAS-No. Value type (Form of exposure) Control parameters / Permissible concentration

| | | exposure) | concentration | | | | |
|-----------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|------------|--|--|--|
| Ganirelix | 124904-93-4 | TWA | 0.2 µg/m3 (OEB 5) | Internal | | | |
| | | Wipe limit | 2 µg/100 cm ² | Internal | | | |
| Engineering measures | to control at vent leakage All engineer design and protect prod | Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to pre- vent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. | | | | | |
| | Totally enclo are required Operations | equire the use of | nd materials transpor appropriate containn akage of compounds | nent tech- | | | |
| Personal protective equipme | ent | | | | | | |
| Respiratory protection | : No personal quired. | respiratory prote | ctive equipment norm | nally re- | | | |
| Hand protection | • | | | | | | |
| Material | : Chemical-re | sistant gloves | | | | | |
| Remarks Eye protection | : Wear safety If the work e mists or aer | nvironment or actorsols, wear the ap | e shields or goggles. tivity involves dusty c opropriate goggles. I face protection if the | | | | |



Ganirelix Formulation

| Version 5.3 | Revision Date: 16.10.2020 | SDS Number: 22210-00016 | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 | | | | |
|----------------|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|
| Skin | and body protection | potential for direct contact to the face with dusts, mists, or aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon the total should be upon the total should be used based upon the total should be upon total | | | | | |
| | | being performed (e.g., sleevelets, apron, gauntlets, disposed skin surfaces. Use appropriate degowning techniques to remove poten contaminated clothing. | | | | | |
| Hygie | ene measures | If exposure to chemical is likely during typical use, provide ey flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of | | | | | |
| | | engineering co appropriate de industrial hygie | ntrols, proper personal protective equipment, gowning and decontamination procedures, ene monitoring, medical surveillance and the trative controls. | | | | |

9. PHYSICAL AND CHEMICAL PROPERTIES

| Appearance | : | Aqueous solution |
|-----------------------------------------------------|---|-------------------|
| Colour | : | No data available |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| рН | : | 5 |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | 100 °C |
| Flash point | : | No data available |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | Not applicable |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | 23 hPa (20 °C) |
| Relative vapour density | : | No data available |
| Relative density | : | 1 |



Ganirelix Formulation

| Version 5.3 | Revision Date: 16.10.2020 | SDS Number 22210-00016 | |
|------------------|----------------------------------------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------------|
| N Par octa | Solubility(ies) Water solubility Partition coefficient: n- octanol/water Auto-ignition temperature | | ely miscible available available |
| Dec | composition temperature | : No data | available |
| N | cosity /iscosity, kinematic losive properties | : No data : Not expl | available osive |
| Oxid | dizing properties ecular weight ticle size | : The sub | stance or mixture is not classified as oxidizing. available available |
| i ui | | . no dulu | |

10. STABILITY AND REACTIVITY

| Reactivity | : | Not classified as a reactivity hazard. |
|-------------------------------------|---|------------------------------------------------|
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reac- | : | Can react with strong oxidizing agents. |
| tions | | |
| Conditions to avoid | : | None known. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | | No hazardous decomposition products are known. |

11. TOXICOLOGICAL INFORMATION

| Information on likely routes of | : | Inhalation |
|---------------------------------|---|--------------|
| exposure | | Skin contact |
| | | Ingestion |
| | | Eye contact |

Acute toxicity

Not classified based on available information.

Components:

Ganirelix:

Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg administration)

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.





| rsion | Revision Date: 16.10.2020 | | Number: 0-00016 | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 |
|---------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| <u>Comp</u> | oonents: | | | |
| Ganir | elix: | | | |
| Speci | es | : R | Rabbit | |
| Metho | bd | : C | Draize Test | |
| Resul | t | : N | Aild eye irritation | |
| Resp | iratory or skin sens | itisation | | |
| Skin s | sensitisation | | | |
| Not cl | assified based on av | ailable inf | formation. | |
| Respi | iratory sensitisatior | า | | |
| Not cl | assified based on av | ailable inf | formation. | |
| <u>Comp</u> | oonents: | | | |
| Ganir | elix: | | | |
| Test 7 | Гуре | : N | Aaximisation Tes | t |
| Speci | es | · (| Guinea pig | |
| | | | | |
| Resul | | | negative | |
| Resul | | | | |
| Resul Germ | t | : n | negative | |
| Resul Germ Not cl | t cell mutagenicity | : n | negative | |
| Resul Germ Not cl | t cell mutagenicity assified based on av ponents: | : n | negative | |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf | formation. | e mutation assay |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: | : n ailable inf : T | formation. | e mutation assay nonella typhimurium |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf : T T | formation. | |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf : T T R | formation. formation. fest Type: revers fest system: Salr Result: negative | nonella typhimurium |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf : T T R T | formation. formation. fest Type: revers fest system: Salr Result: negative | nonella typhimurium e mutation assay |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf : T R T T T T | formation. formation. fest Type: revers fest system: Salr Result: negative fest Type: revers | nonella typhimurium e mutation assay |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf : T R T R | formation. Test Type: reverse Test system: Salre Result: negative Test Type: reverse Test system: Esc Result: negative | nonella typhimurium e mutation assay herichia coli |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf : T R T R T T R | formation. formation. fest Type: revers est system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro | nonella typhimurium e mutation assay herichia coli |
| Resul Germ Not cl <u>Comp</u> Ganir | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf : T R T R T T R T T T | formation. formation. fest Type: revers est system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro | nonella typhimurium e mutation assay herichia coli o assay |
| Resul Germ Not cl Comp Ganir Genot | t cell mutagenicity assified based on av ponents: relix: | : n ailable inf : T R T R T R T R | formation. Fest Type: revers Test system: Salr Result: negative Test Type: revers Test system: Esc Result: negative Test Type: in vitro Test system: Chir Result: negative | nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells |
| Resul Germ Not cl Comp Ganir Genot | t cell mutagenicity assified based on av <u>ponents:</u> relix: toxicity in vitro | : n ailable inf : T T R T R T R T S | formation. formation. fest Type: revers fest system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro fest system: Chir Result: negative fest Type: In vivo Species: Mouse | nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells |
| Resul Germ Not cl Comp Ganir Genot | t cell mutagenicity assified based on av <u>ponents:</u> relix: toxicity in vitro | : n ailable inf : T R T R T R T R S A | formation. formation. fest Type: revers fest system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro fest system: Chir Result: negative fest Type: In vivo Species: Mouse Application Route | nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells |
| Resul Germ Not cl Comp Ganir Genot | t cell mutagenicity assified based on av <u>ponents:</u> relix: toxicity in vitro | : n ailable inf : T R T R T R T R S A | formation. formation. fest Type: revers fest system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro fest system: Chir Result: negative fest Type: In vivo Species: Mouse | nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells |
| Resul Germ Not cl Comp Ganir Genot | t cell mutagenicity assified based on av <u>ponents:</u> relix: toxicity in vitro | : n ailable inf : T R T R T R T R R R R R R R R R | formation. Fest Type: reverse Fest system: Salre Result: negative Fest Type: reverse Fest Type: reverse Fest Type: in vitro Fest | nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells |

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Ganirelix Formulation



| Version 5.3 | Revision Date: 16.10.2020 | | DS Number: 210-00016 | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 |
|----------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| <u>Co</u> | <u>mponents:</u> | | | |
| | nirelix: acts on fertility | Test Type: Fertility/early embryonic Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 W Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Test Type: Fertility/early embryonic | | : Subcutaneous Treatment: 13 Weeks).1 μg/kg fertility y/early embryonic development |
| | | | Fertility: LOAEL: 1 | : Subcutaneous Treatment: 8 Weeks ΙΟ μg/kg on mating performance, Effects on fertility |
| | | | Species: Monkey Application Route | : Subcutaneous 0.02 mg/kg body weight |
| Effe mei | ects on foetal develop- nt | : | Species: Rat, fem Application Route | : Subcutaneous icity: LOAEL: 10 μg/kg |
| | | | Species: Rabbit, f Application Route | : Subcutaneous icity: LOAEL: 30 μg/kg |
| | productive toxicity - As- sment | : | ity, based on anim | adverse effects on sexual function and fertil- nal experiments., Some evidence of adverse oment, based on animal experiments. |

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Components:

Ganirelix:

| Exposure routes Target Organs Assessment | : | Ingestion Bone marrow, Liver, Adrenal gland, spleen, Ovary Causes damage to organs through prolonged or repeated |
|------------------------------------------------|---|------------------------------------------------------------------------------------------------------------------------|
| | | exposure. |





| /ersion 5.3 | Revision Date: 16.10.2020 | SDS Number: 22210-00016 | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 |
|----------------|-------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| Repe | ated dose toxicity | | |
| Com | ponents: | | |
| Gani | relix: | | |
| Expo | EL | : Rat : 0.02 mg/kg : 2 mg/kg : Subcutaneous : 6 Months : Bone marrow | |
| Expo | | : Mouse, female : 0.3 mg/kg : Subcutaneous : 3 Months : Liver, Adrenal g | gland, spleen, Ovary |
| Expo | | : Mouse, male : 3 mg/kg : Subcutaneous : 3 Months : Liver, Adrenal g | gland, spleen |
| | EL cation Route sure time | : Monkey : 2.5 mg/kg : Subcutaneous : 6 Months : No significant a | adverse effects were reported |
| • | ration toxicity lassified based on ava | ilable information. | |
| Expe | rience with human e | xposure | |
| • | | | |

Components:

Ganirelix:

Inhalation

Symptoms: The most common side effects are:, vaginal bleeding, Headache, Abdominal pain, Nausea, ectopic pregnancy, miscarriage

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ganirelix:

Ecotoxicology Assessment

| Acute aquatic toxicity | : | No data available |
|------------------------|---|-------------------|
|------------------------|---|-------------------|

:

| Chronic aquatic toxicity | : | No data available |
|--------------------------|---|-------------------|
|--------------------------|---|-------------------|

Ganirelix Formulation



| Version 5.3 | Revision Date: 16.10.2020 | SDS Number: 22210-00016 | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 |
|----------------------------|-------------------------------------------------------|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | i stence and degrada ata available | bility | |
| | ccumulative potentia ata available | l | |
| | lity in soil ata available | | |
| | r adverse effects ata available | | |
| 13. DISPC | SAL CONSIDERATI | ONS | |
| Wast | osal methods e from residues aminated packaging | : Empty contain dling site for re | accordance with local regulations. ers should be taken to an approved waste han- ecycling or disposal. e specified: Dispose of as unused product. |
| 14. TRAN | SPORT INFORMATIO | DN | |
| Interi | national Regulations | | |
| UNR ⁻ Not re | TDG egulated as a dangerc | ous good | |
| | -DGR egulated as a dangerd | ous good | |
| | -Code egulated as a dangero | ous good | |
| | sport in bulk accordi pplicable for product a | ng to IMO instrumen as supplied. | ts |
| 15. REGU | LATORY INFORMAT | ION | |
| Safet ture | y, health and enviro | nmental regulations/ | legislation specific for the substance or mix |
| The c AICS | • • | roduct are reported : not determined | in the following inventories: |
| | | | |
| DSL | | : not determined | t de la constante de |

16. OTHER INFORMATION

Further information

| Sources of key data used to | : | Internal technical data, data from raw material SDSs, OECD |
|-----------------------------|---|------------------------------------------------------------|
| compile the Safety Data | | eChem Portal search results and European Chemicals Agen- |





| Version 5.3 | Revision Date: 16.10.2020 | SDS Number: 22210-00016 | Date of last issue: 13.09.2019 Date of first issue: 15.10.2014 |
|----------------|------------------------------|----------------------------|-------------------------------------------------------------------|
| Sheet | | cy, http://ech | a.europa.eu/ |
| Date format | | : dd.mm.yyyy | |

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response: ELx - Loading rate associated with x% response: EmS - Emergency Schedule: ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose): MARPOL - International Convention for the Prevention of Pollution from Ships: n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level: NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN